Managing high cholesterol takes vigilance. Too often, as Dr. Ann Marie Navar explains, therapeutic inertia keeps patients from reaching their risk-based LDL-C goals. https://bit.ly/4icbcWK
NewAmsterdam Pharma Corporation
生物技术
Aventura，Florida 8,774 位关注者
NewAmsterdam Pharma Corporation is a clinical-stage biopharma company creating therapies for cardiometabolic diseases.
关于我们
This page is intended for US audiences. Founded in 2019, NewAmsterdam Pharma Corporation is a late-stage clinical biopharmaceutical company focused on the research and development of transformative therapies for cardiometabolic diseases. Its mission is to improve patient care in populations where traditional therapies have been unsuccessful or are not tolerated. The Company is investigating a selective cholesteryl ester transfer protein (CETP) inhibitor as an LDL-C lowering therapy for patients who cannot be treated optimally with currently available lipid-lowering therapy or for patients with Atherosclerotic Cardiovascular Disease/Familial Hypercholesterolemia (ASCVD/FH) on maximally tolerated statin therapy.
- 网站
-
https://www.newamsterdampharma.com
NewAmsterdam Pharma Corporation的外部链接
- 所属行业
- 生物技术
- 规模
- 11-50 人
- 总部
- Aventura，Florida
- 类型
- 上市公司
- 创立
- 2019
地点
-
主要
获取路线
US，Florida，Aventura
NewAmsterdam Pharma Corporation员工
动态
-
TRIAL UPDATE: Positive topline results from our Phase 3 TANDEM study evaluating our investigational CETP inhibitor and ezetimibe as a fixed-dose combination in patients with heterozygous familial hypercholesterolemia (HeFH), ASCVD, or multiple ASCVD risk factors: https://bit.ly/4fRSZf1
-
Listen in to a fireside chat with three of our senior leaders as part of the Jefferies London Healthcare Conference on Thursday, Nov. 21. Learn how to join the live webcast or access an archived replay: https://bit.ly/3OckSCO
-
-
New, late-breaking data was presented today at #AHA24 from our Phase 3 BROOKLYN clinical trial evaluating the efficacy and safety of obicetrapib, our investigational CETP inhibitor, in patients with heterozygous familial hypercholesterolemia. https://bit.ly/3AZcSBX
-
We’re honored to be a finalist in the European Lifestars Awards - Celebrating Life Science Leaders for Post-IPO Equity Raise of the Year and proud of our CEO, Michael Davidson, who is a finalist for Public Company CEO of the Year. The crystal trophies will be awarded tonight! https://bit.ly/3Cz1w8p
-
-
Familial hypercholesterolemia (FH) is a common genetic disorder that leads to extremely high LDL-C levels. Our Phase 3 BROOKLYN trial focused on patients with this tough-to-treat diagnosis, and the results are being shared at #AHA24.??
-
When high cholesterol runs in the family, a common genetic condition called familial hypercholesterolemia (FH) could be the culprit. FH is characterized by very high, persistent LDL-C levels. #AHA24
-
Find us at #AHA24 booth #1112 to learn about the significant unmet need for lipid-lowering therapies and explore how we’re working to address it.
-
Out with the old – in with the New! We’re unveiling a fresh new website. Dive into the history of our company, our investigational CETP inhibition programs, and current research: https://bit.ly/4cnyogC
-
-
Today, more than 2,500 Americans will die due to cardiovascular disease. As we prepare for #AHA24, we’re launching a new effort to encourage everyone to expect more when it comes to reducing LDL-C and its associated risk of cardiovascular disease. Learn more at: https://lnkd.in/e-safkDR.
-